Comparison of Lasers in the Treatment of Scars
1550-nm Non Ablative Laser (Fraxel) Versus Ablative 10,600-nm Carbon Dioxide (CO2) Fractional Laser in the Treatment of Surgical and Traumatic Scars: A Comparison Study on Efficacy, Treatment Regimen, and Cost.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Health Care, Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 or older.
- Fitzpatrick skin type I-IV.
- Scars secondary to surgery or trauma.
- Scar length minimum 4 cm in length.
Exclusion Criteria:
- Scars less than 6 weeks old.
- History of keloid scarring.
- Use of isotretinoin currently or within 3 months of enrollment
- Use of photosensitive medication currently or within 3 months of enrollment.
- Pregnancy -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Scar treated with Fraxel and CO2 laser
One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
|
One half of the scar is treated with Fraxel Laser
One half of the scar is treated with CO2 Laser.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scar Pain
Time Frame: Baseline and 6 months
|
Patient and Observer Scar Assessment Scale (POSAS).
Minimum of 1 and maximum of 10 (higher score is equivalent to a worse outcome).
These are patient recorded scores.
|
Baseline and 6 months
|
|
Scar Itching
Time Frame: Baseline and 6 months
|
Patient and Observer Scar Assessment Scale (POSAS).
Minimum of 1 and maximum of 10 (higher score is equivalent to a worse outcome).
These are patient recorded scores.
|
Baseline and 6 months
|
|
Scar Color
Time Frame: Baseline and 6 months
|
Patient and Observer Scar Assessment Scale (POSAS).
Minimum of 1 and maximum of 10 (higher score is equivalent to a worse outcome).
These are patient recorded scores.
|
Baseline and 6 months
|
|
Scar Stiffness
Time Frame: Baseline and 6 months
|
Patient and Observer Scar Assessment Scale (POSAS).
Minimum of 1 and maximum of 10 (higher score is equivalent to a worse outcome).
These are patient recorded scores.
|
Baseline and 6 months
|
|
Scar Thickness
Time Frame: Baseline and 6 months
|
Patient and Observer Scar Assessment Scale (POSAS).
Minimum of 1 and maximum of 10 (higher score is equivalent to a worse outcome).
These are patient recorded scores.
|
Baseline and 6 months
|
|
Scar Irregularity
Time Frame: Baseline and 6 months
|
Patient and Observer Scar Assessment Scale (POSAS).
Minimum of 1 and maximum of 10 (higher score is equivalent to a worse outcome).
These are patient recorded scores.
|
Baseline and 6 months
|
|
Overall Opinion
Time Frame: Baseline and 6 months
|
Patient and Observer Scar Assessment Scale (POSAS).
Minimum of 1 and maximum of 10 (higher score is equivalent to a worse outcome).
These are patient recorded scores.
|
Baseline and 6 months
|
|
Patient Satisfaction
Time Frame: 6 months
|
Patients rated how satisfied they were with the appearance of each half of the treated scar.
|
6 months
|
|
Observer Total Score
Time Frame: Baseline and 6 months.
|
Change in total observer score made up of components rating the scar appearance based on photos at baseline and photos at 6 months.
Scale includes the following components: Visual analog scale from 0 to 10 (with 0 being excellent appearance and 10 being worst appearance), scar color, contour and distortion (these 3 measures were graded from 1 to 4 with 1 equating to perfect and 4 equating to worst appearance), scar finish (matte scar was given a score of 1 and shiny scar was given a score of 2).
The total score of the above components provided an overall observer score, with 4 being the best score possible (equating to best appearing scar) and 24 being the worst score possible (equating to worst appearing scar).
|
Baseline and 6 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pooja Chitogopeker, MD, University of Iowa
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 201509722
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.